Big pharma mergers unlikely in Indian market soon

Dr. Reddy's Laboratories' managing director, GV Prasad, stated that large mergers in the Indian pharmaceutical market are unlikely due to uncertainties. The company is focusing on diversifying its portfolio and investing in research and development for branded generics and consumer health. Dr. Reddy's reported revenue of ₹28,000 crore in FY24 and is shifting towards branded franchises. The company is also expanding into over-the-counter (OTC) drugs, leveraging its existing consumer care business and exploring acquisitions in this area. The Indian pharmaceutical market continues to grow, driven by rising income levels and healthcare demand. Dr. Reddy's is also addressing the obesity issue, planning to enhance its capabilities in this competitive sector while monitoring the safety of obesity drugs.